Literature DB >> 8659495

Effects of steroids on the progression of renal failure in chronic interstitial renal fibrosis: a pilot study in Chinese herbs nephropathy.

J L Vanherweghem1, D Abramowicz, C Tielemans, M Depierreux.   

Abstract

Chinese herbs nephropathy is characterized by an extensive interstitial fibrosis and by a rapid evolution to end-stage renal failure. We thus decided to try steroid therapy (prednisolone 1 mg/kg for 1 month, tapered off 0.1 mg/kg every 2 weeks) in cases with moderate renal failure and evidence of deterioration in renal function. Our steroid group (SG) consisted of 12 female patients with biopsy-proven renal fibrosis who were followed for at least 12 months after the initiation of steroids. Plasma creatinine level (Pcreat) ranged from 1.8 to 3.9 mg/dL (mean +/- SEM, 2.8 +/- 0.2 mg/dL) when steroids were initiated at t = 0. Renal failure was in progression since Pcreat was 2.1 +/- 0.1 mg/dL (P = 0.022) 3 months before t = 0. Our control group (CG; N = 23) was selected retrospectively from among the 81 patients in the Belgian Register of Chinese Herbs Nephropathy. Compared with the CG, renal function was better preserved in the SG (Pcreat; mean +/- SEM): SG v CG, 2.9 +/- 0.3 mg/dL v 5.3 +/- 0.5 mg/dL at 6 months (P = 0.0024) and 4.0 +/- 0.7 mg/dL v 7.1 +/- 0.5 mg/dL at 1 year (P = 0.001). The slope of the reciprocal serum creatinine concentration was similar in both groups before t = 0 (-0.0463 mg/dL/mo in the SG v -0.0438 mg/dL/mo in the CG; P = 0.83), but it became less steep after initiation of steroid therapy (between 0 and 6 months, -0.000742 mg/dL/mo in the SG v -0.0284 mg/dL/mo in the CG; P < 0.001). Finally, only two of the 12 patients in the SG required dialysis at 1 year compared with 16 of the 23 patients in the CG (P = 0.0045). We conclude that steroid therapy slows the progression of renal failure in a disease characterized by an interstitial fibrosis that progresses quickly despite the fact that the insulting agent has been withdrawn. This supports the hypothesis that renal interstitial fibrosis may be an immune-mediated process.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8659495     DOI: 10.1016/s0272-6386(96)90542-9

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  15 in total

1.  Isogenic mesenchymal stem cells transplantation improves a rat model of chronic aristolochic acid nephropathy via upregulation of hepatic growth factor and downregulation of transforming growth factor β1.

Authors:  Wei Li; Hong Jiang; Jiang-Min Feng
Journal:  Mol Cell Biochem       Date:  2012-06-04       Impact factor: 3.396

Review 2.  Aristolochic acid nephropathy: epidemiology, clinical presentation, and treatment.

Authors:  Randy L Luciano; Mark A Perazella
Journal:  Drug Saf       Date:  2015-01       Impact factor: 5.606

3.  Chinese herb nephropathy.

Authors:  M M Meyer; T P Chen; W M Bennett
Journal:  Proc (Bayl Univ Med Cent)       Date:  2000-10

Review 4.  Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date.

Authors:  Jean-Pierre Cosyns
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 5.  The involvement of mycotoxins in the development of endemic nephropathy.

Authors:  Maja Peraica; Ana-Marija Domijan; Marica Miletić-Medved; Radovan Fuchs
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

6.  A PTBA small molecule enhances recovery and reduces postinjury fibrosis after aristolochic acid-induced kidney injury.

Authors:  Tatiana Novitskaya; Lee McDermott; Ke Xin Zhang; Takuto Chiba; Paisit Paueksakon; Neil A Hukriede; Mark P de Caestecker
Journal:  Am J Physiol Renal Physiol       Date:  2013-12-26

7.  Preventing aristolochic acid nephropathy.

Authors:  Nelomi Anandagoda; Graham M Lord
Journal:  Clin J Am Soc Nephrol       Date:  2015-01-13       Impact factor: 8.237

Review 8.  Experimental Aristolochic Acid Nephropathy: A Relevant Model to Study AKI-to-CKD Transition.

Authors:  Thomas Baudoux; Inès Jadot; Anne-Emilie Declèves; Marie-Hélène Antoine; Jean-Marie Colet; Olivia Botton; Eric De Prez; Agnieszka Pozdzik; Cécile Husson; Nathalie Caron; Joëlle L Nortier
Journal:  Front Med (Lausanne)       Date:  2022-05-04

9.  Smad7 protects against chronic aristolochic acid nephropathy in mice.

Authors:  Xiao-Yu Dai; Li Zhou; Xiao-Ru Huang; Ping Fu; Hui-Yao Lan
Journal:  Oncotarget       Date:  2015-05-20

Review 10.  Chinese herbs containing aristolochic acid associated with renal failure and urothelial carcinoma: a review from epidemiologic observations to causal inference.

Authors:  Hsiao-Yu Yang; Pau-Chung Chen; Jung-Der Wang
Journal:  Biomed Res Int       Date:  2014-08-27       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.